[ad_1]
Merdeka.com – The value of the shares of the pharmaceutical and biotech company, Gilead Sciences, shot up more than 16 percent on the US stock exchanges. USA A spike in stocks after Gilead successfully conducted Remdesivir drug trials on covid-19 patients at Chicago university hospitals.
Kathleen Mullane, an infectious disease specialist at the University of Chicago, said that most covid-19 patients with serious conditions experienced a rapid recovery from symptoms of fever and respiratory disorders. So that the hospital can be discharged in less than a week.
“The good news is that most of our patients have been discharged, which is very good. We only found two patients who died,” Kathleen Mullane told STAT News, CNBC reported Friday.
According to him, at the trial, the Chicago university hospital recruited 125 corona patients, of whom 113 were in severe severity. Although the Gilead company recorded up to 4,000 patient data for the tests.
President Donald Trump also warmly welcomed the drug Remdesivir and malaria, hydroxychloroquine, which is considered something interesting amid panic by American citizens. Therefore, both drugs are being clinically tested to examine their effectiveness in treating patients aged 19 years.
1 of 2 pages
The same remedy for SARS and MERS
The medicine Remdesivir is not really a new medicine. Because, it has been used to treat patients with SARS and MERS, which is also caused by the coronavirus group.
Some health authorities in the US The United States, China, and other countries also used remdesivir as a treatment when the Ebola outbreak occurred several years ago.
Therefore, remdesivir is expected to reduce the duration of treatment for patients with covid-19. The results of the Gilead clinical trial in patients with the virus in serious conditions are expected to be completed in April 2020. Hopefully the drug can be published in May 2020.
2 of 2 pages
[ad_2]
